<?xml version="1.0" encoding="utf-8"?>
<Document>
  <Do_id>16237304</Do_id>
  <Journal>Clinical nuclear medicine</Journal>
  <Doc_title>F-18 FDG PET for assessing tyrosine kinase-related signal transduction inhibition in a GIST c-kit-positive tumor patient by imatinib.</Doc_title>
  <Doc_abstract>None</Doc_abstract>
  <Doc_ChemicalList>Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Radiopharmaceuticals;Fluorodeoxyglucose F18;Imatinib Mesylate;Protein-Tyrosine Kinases</Doc_ChemicalList>
  <Doc_meshdescriptors>Antineoplastic Agents;Benzamides;Fluorodeoxyglucose F18;Gastrointestinal Stromal Tumors;Humans;Imatinib Mesylate;Male;Middle Aged;Piperazines;Positron-Emission Tomography;Protein-Tyrosine Kinases;Pyrimidines;Radiopharmaceuticals;Signal Transduction;Treatment Outcome</Doc_meshdescriptors>
  <Doc_meshqualifiers>administration &amp; dosage;diagnostic imaging;drug therapy;enzymology;administration &amp; dosage;methods;antagonists &amp; inhibitors;administration &amp; dosage;drug effects</Doc_meshqualifiers>
</Document>
